Antimicrobial

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

LEXINGTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection…

1 year ago

CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc.…

1 year ago

OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now availableAdded reporting customized for the needs of hospital epidemiologists…

1 year ago

Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board

BOULDER, CO / ACCESSWIRE / August 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing…

1 year ago

Aridis Pharmaceuticals Announces $2 Million Offering

Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the…

1 year ago

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements

LEXINGTON, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing…

1 year ago

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Spero to receive $30…

1 year ago

Recce Pharmaceuticals to Present at the 2023 Military Health System Research Symposium (MHSRS)

SYDNEY, Australia, July 31, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing…

1 year ago